Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2022 · 10-Q
Revenue$128.78M$128.78M+6.1% vs Q3 2021 Net Income-$36.85M-$36.85MN/M vs Q3 2021 EPS Diluted-$0.30-$0.30N/M vs Q3 2021 Gross Profit$48,893,000+3.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,272,000N/M Free Cash Flowderived-$24,116,000N/M Margins · derivedGross margin38.0%−1.0 pt vs Q3 2021
Operating margin-30.7%+2.0 pt vs Q3 2021
Net margin-28.6%−11.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end